FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# OMB APPROVAL OMB Number: 32350104 Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Chen Ruoyu	Requiring Sta (Month/Day/Y	2. Date of Event Requiring Statement (Month/Day/Year) 10/30/2023  3. Issuer Name and Ticker or Trading Symbol GYRE THERAPEUTICS, INC. [ GYRE ]						
(Last) (First) (Middle) C/O GYRE THERAPEUTICS, INC. 12730 HIGH BLUFF DRIVE, SUITE			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)		
250	m		X Officer (give title below)  Interim C	Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting		
(Street) SAN DIEGO CA 92130			merini Ci	ΓU			Person	by More than One Person
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
Та	ble I - Non-D	Derivativ	ve Securities Benefic	ially O	wned			
Ta 1. Title of Security (Instr. 4)	ble I - Non-D	2	2. Amount of Securities Beneficially Owned (Instr.	3. Owner Form: I (D) or II (I) (Inst	ership Direct ndirect		ture of Indire	ct Beneficial 5)
1. Title of Security (Instr. 4)	Table II - De	2 B 4 Privative	2. Amount of Securities Beneficially Owned (Instr.	3. Owner Form: I (D) or II (I) (Inst	ership Direct ndirect r. 5)	Owne		
1. Title of Security (Instr. 4)	Table II - De	erivative s, warran	2. Amount of Securities Beneficially Owned (Instr. I) Securities Beneficia	3. Owner Form: I (D) or II (I) (Institute Securities	ership Direct ndirect r. 5)	Owne sion cise		

**Explanation of Responses:** 

### Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

/s/ Branden Berns, as attorney-in-fact for Ruoyu 11/01/2023

Chen

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- $^{**} \ Intentional \ misstatements \ or \ omissions \ of facts \ constitute \ Federal \ Criminal \ Violations \ See \ 18 \ U.S.C. \ 1001 \ and \ 15 \ U.S.C. \ 78 \ ff(a).$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### **POWER OF ATTORNEY**

Know all by these presents that the undersigned hereby constitutes and appoints each of Ying Luo, Thomas Wilson Eastling, Branden Berns, and Ryan Murr, and any of their substitutes, signing singly, as the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other document necessary or appropriate to obtain codes, passwords, and passphrases enabling the undersigned to make electronic filings with the SEC of reports require by the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- 2. execute for and on behalf of the undersigned, in the undersigned's capacity as a director, officer and/or ten percent stockholder of Catalyst Biosciences, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any securities exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned also ratifies hereby any action previously taken by each attorney-in-fact that would have been authorized by this power of attorney if it has been in effect at the time such action was taken. The undersigned acknowledges that each attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of June 14, 2023.

By: <u>/s/ Ruoyu Chen</u> Name: Ruoyu Chen